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Purpose: Continuous renal replacement therapy (CRRT) has been established for 
critically ill acute kidney injury (AKI) patients. In addition, some centers consist of 
a specialized CRRT team (SCT) with physicians and nurses. To our best knowl-
edge, however, ona a few studies have yet been carried out on the superiority of 
SCT management. Materials and Methods: A total of 551 patients, who received 
CRRT between January 2008 and March 2009, were divided into two groups based 
on the controller of CRRT. The impact of the CRRT management on 28-day mor-
tality was compared between two groups by Kaplan-Meier curve and Cox analysis. 
Results: During the study period, the number of filters used, down-time per day, 
and intensive care unit length of day were significantly higher in non-SCT group 
than in SCT group (6.2 hrs vs. 5.0 hrs, p=0.042; 5.0 hrs vs. 3.8 hrs, p<0.001; 27.5 
days vs. 21.1 days, p=0.027, respectively), while net ultrafiltration rate was signifi-
cantly lower in non-SCT group than SCT group (28.0 mL/kg/hr vs. 29.5 mL/kg/hr, 
p=0.043, respectively). In addition, 28-day mortality rate was significantly lower in 
SCT group than with non-SCT group (p=0.031). Moreover, Cox regression analy-
sis showed that 28-day mortality rate was significantly lower in SCT control group, 
even after adjusting for age, gender, severity scores, biomarkers, risk, injury, failure, 
loss, and end-stage renal disease, and contributing factors (hazard ratio 0.91, 
p=0.046). Conclusion: A well-trained CRRT team could be beneficial for mortality 
improvement of AKI patients requiring CRRT.
Key Words:   SCT management, acute kidney injury, continuous renal replace-
ment therapy, 28-day mortality 
INTRODUCTION
Severe acute kidney injury (AKI) is a well-known complication in critically ill pa-
tients and has a significant impact on morbidity, mortality, and health resource uti-
lization in these patients.1-5 Although general treatment such as fluid and hemody-
namic optimization was provided only for these patients in the past,6 continuous 
renal replacement therapy (CRRT) has been recently an essential part of critical 
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YUHS, Seoul, Korea. Demographic, clinical, and biochemi-
cal data at the time of CRRT initiation were recorded. For the 
assessment of disease severity, Sequential Organ Failure As-
sessment (SOFA) score, Acute Physiology and Chronic 
Health Evaluation (APACHE) II score, and Charlson Co-
morbidity Index (CCI) were also calculated at the start of 
CRRT. Moreover, we counted the transfused number of 
packed red blood cell (RBC) during the period of CRRT 
treatment except for transfusions conducted due to active 
bleeding. Such active bleeding is considered to be a situa-
tion when the patients need transfusion of more than 10 
units of packed RBCs within 24 hrs or are bleeding more 
than 1- to 1.5-fold of the body’s entire blood volume as pre-
viously described.13 Down-time (hours/day) was defined as 
the period of time when CRRT was not applied between the 
initiation and end of CRRT, as defined by Uchino, et al.14
Definitions and SCT roles
SCT is defined as a team including physicians and nurses 
especially trained and educated in performing CRRT. The 
members of SCT are composed of 2 specialized nephrolo-
gists, 2 nephrologic fellows, an ICU specialist, 3 ICU resi-
dents, and 5 CRRT specialized nurses. They create and 
share the educational programs and management protocol 
care, and is considered an established treatment modality 
for AKI patients.7 However, the mortality rate in these pa-
tients still remains extremely high,8-10 even though the tech-
nical devices for CRRT management have been advanced 
recently. Given the complexity of AKI progression and 
handling of extracorporeal system, high qualified CRRT 
managements, which include proper exchanges of extracor-
poreal circuits, frequent monitoring for dose of CRRT and 
optimal anticoagulation, and replacement of electrolytes, 
are regarded as one of potential candidates for improving 
patient’s outcomes.9,11
Some centers operate a specialized CRRT team (SCT) 
with nurses and physicians from their disciplines,12 and 
they surmise that clinical outcomes of the patients treated 
by SCT should be superior to those from non-SCT. Howev-
er, to our best knowledge, only a few studies have been car-
ried out on the comparison between before and after SCT 
approach.12 Therefore, we investigated the benefit of SCT 
management for 28-day all-cause mortality of AKI patients 
treated with CRRT. In addition, we initiated the SCT ap-
proach for the management of CRRT in August 2008, 
therefore, we compared the outcomes and quality of CRRT 
management based on the SCT management.
MATERIALS AND METHODS
Patients
A total of 640 intensive care unit (ICU) patients who re-
ceived CRRT for severe AKI between January 2008 and 
March 2009 were initially analyzed. We excluded 89 pa-
tients who died within the first 24 hours of CRRT, were less 
than 18 years of age, were on chronic dialysis, or were di-
agnosed with terminal malignancy and less than 3 month-
life expectancy. In the final analysis, 551 patients were en-
rolled and investigated. The SCT was set up in August 2008, 
therefore, we divided patients into two groups, based on 
that point (Fig. 1).
The study protocol was approved by the Institutional Re-
view Board (IRB) of Yonsei University Health System 
(YUHS) Clinical Trial Center. Since this study was a retro-
spective medical record-based study and the study subjects 
were de-identified, the IRB waived the need for a written 
consent from the patients.
Data collection
Patients’ data were retrieved from the CRRT Database of 
SCT activity started 
August 1, 2008
ICU patients received CRRT between 
January 2008 and March 2009 (n=640)
Patients received CRRT 
due to AKI (n=551)
Patients received CRRT 
by non-SCT (n=253)
August 1, 2007–July 31, 2008
Patients received CRRT 
by SCT (n=298)
August 1, 2008–March 31, 2009
Exclusion (n=89);
  Died within the first 24 hrs 
    of CRRT (n=21)
  Less than 18 years of age 
    (n=15)
  Chronic dialysis patients 
    (n=37)
  Terminal malignancy (n=16)
Fig. 1. Flow diagram of patient selection and outcomes. A total of 640 ICU 
patients who received CRRT for severe AKI between August 2007 and 
September 2009 were initially analyzed. We excluded 89 patients because 
they died within the first 24 hours of CRRT, were less than 18 years of age, 
were on chronic dialysis, or were diagnosed with terminal malignancy 
which was considering less than 3 month-life expectancy. In the final anal-
ysis, 551 patients were enrolled and investigated. ICU, intensive care; 
CRRT, continuous renal replacement therapy; AKI, acute kidney injury; non-
SCT, conventional team approach; SCT, specialized CRRT team.
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with CRRT, and checks hemodynamic stability, removal 
rate of ultrafiltration, and CRRT kit status etc. Their primary 
role is CRRT management, apart from ICU general care 
performed by bed-side nurses. In addition, they are also in 
charge to educate bed-side nurses on basic CRRT-handling 
methods every three months. Based on daily rounds with 
specialized team, they discussed and tried to solve the poten-
tial problems on the management of CRRT (Table 1 and 2).12 
 
ICU setting
The investigation site was a self-contained, 112-bed medi-
cal and surgical ICU in a 2089-bed teaching hospital in 
Seoul, Korea that was equipped with 15 CRRT machines. 
The decisions related CRRT treatment make no difference 
between before and after SCT group, because they are de-
termined by same nephrologist. One bed-side nurse cared 2 
ICU patients, but they also had to perform monitoring and 
maintenance of the CRRT system before SCT set-up. How-
ever, after SCT approach, additional nursing cares were 
available for CRRT care.
CRRT protocol
Vascular access for CRRT was approached via femoral, in-
ternal jugular, or subclavian vein route. In most patients, 
continuous veno-venous hemodiafiltration was performed 
using the PRISMA (Gambro, Hechingen, Germany) plat-
form. CRRT was initiated at a blood flow rate of 100 mL/
min, which was gradually increased to 150 mL/min. The ul-
trafiltration dose was prescribed as 35 mL/kg/hr, and Hemo-
sol (Gambro) was replaced by predilution method. We also 
measured delivered drainage amount daily and recorded it to 
calculate delivered CRRT dose. CRRT circuits were ex-
changed, if the blood pump stopped. However, circuit-ex-
changes were conducted regularly after 48 hrs of use, even 
if the blood pumps were not stopped.
Statistical analysis
Statistical analysis was performed using SPSS for Windows, 
on CRRT. Additionally, a monthly quality control to correct 
management protocols and problems about CRRT such as 
electrolytes, coagulation, and hemodynamic status is per-
formed. SCT team has complementary roles to each other. 
ICU specialist and residents have a primary responsibility 
for patient general care and perform overall decision mak-
ings about medical problems of ICU patients. Especially, 
nephrologists are authorized to initiate, maintain and stop 
CRRT and switch to intermittent hemodialysis or peritoneal 
dialysis. They decide to start CRRT based on patients’ he-
modynamic status, declining urine output, electrolyte and 
acid-base imbalances. They also settled mode and dose of 
CRRT, and net ultrafiltration rate during CRRT. In nursing 
part, CRRT-nurses work on three shifts daily. He/she goes 
around ICU at regular interval to monitor the patients treated 
Table 1. The Modules of Educational Program for SCT Nurses
Module Lessons In-practice training
I General intensive care course 72 hrs 80 hrs on general ICU
II CRRT specialist training course 16 hrs 32 hrs on general ICU
CRRT, continuous renal replacement therapy; SCT, specialized CRRT team; ICU, intensive care unit; AKI, acute kidney injury.
Module I is corresponded to all ICU nurses. Module II is relevant to SCT nurses for CRRT. Module I includes several topics about the general management 
of AKI patients including nursing care for CRRT patients and practical installation and monitoring of the CRRT machine. CRRT specialist training course; 
basic principles and optimal prescription for CRRT, overview and practical operation of CRRT, trouble shooting in CRRT, assessment and management of 
failed dialysis catheter.
Table 2. The Protocol for Replacement of Electrolytes and 
Anticoagulation during CRRT
Electrolytes
    K+ (mEq/L)
        >4.5 No KCl mix in the 5 L hemozol®
        3.6‒4.5 20 mEq KCl mix in the 5 L hemozol®
        <3.6 40 mEq KCl mix in the 5 L hemozol®
    P (mEq/L)
        ≥2.0 No phosten® mix in the 5 L hemozol®
        <2.0 20 mL phosten® mix in the 5 L hemozol®
Anticoagulation
    Initial
        High risk No anticoagulation/saline flushing
        Low risk Systemic heparinization
    Maintenance
        High risk-1 No anticoagulation/saline flushing
        High risk-2 Regional anticoagulation   (citrate or nafamostat)
        Low risk Systemic heparinization
CRRT, continuous renal replacement therapy.
Potassium and phosphate level check 2 times per day. Phosten®; potas-
sium phosphate. Hemosol®; hemozol B0. Definitions; 1) High risk; active 
bleeding, post-operative within 48 hours, low platelet count <50000/mm3, 
prolonged PT/PTT ≥2.0 INR/60 sec. 2) Low risk; all patients except for high 
risk patients. 3) High risk-1 and high risk-2 were divided according to as-
sessment of clotting in extracorporeal system during CRRT.
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Comparisons of clinical outcomes between the two 
groups during follow-up duration
The total CRRT time, down-time per day, RBC-transfused 
numbers, and ICU length of days during CRRT treatment 
were significantly lower under SCT management compared 
to the group under non-SCT, while net ultrafiltration rate in 
SCT group was significantly higher than that in the non-
SCT group. Moreover, the numbers of dialyzers used dur-
ing 48 hrs in two groups for evaluating circuit failure was 
also significantly lower in SCT group than those in the non-
SCT group (Table 4).
SCT is independently associated with 28-day patients’ 
survival
During the follow-up duration, 28-day all-cause mortality 
was significantly higher in the non-SCT group than in the 
SCT group (69.5% vs. 55.3%, p=0.031) (Table 4). In addi-
tion, Kaplan-Meier plots also showed that the 28-day all-
cause mortality was significantly higher in the non-SCT 
group (p=0.016) (Fig. 2). Cox regression analysis revealed 
that the crude 28-day mortality rate was significantly lower 
in the SCT group than in the non-SCT group (HR: 0.77; 95% 
CI: 0.63‒0.95; p=0.016) (Model 1). Moreover, the lower 
mortality rate in the SCT group remained significant even af-
ter adjusting for age, gender, mean arterial pressure, CRP lev-
el, and APACHE II, and SOFA scores (HR: 0.76; 95% CI: 
0.58‒0.98; p=0.039) (Model 2). Furthermore, additional ad-
justments for Hb, serum albumin, total cholesterol, and total 
bilirubin levels still revealed that SCT was significantly asso-
ciated with reducing 28-day all-cause mortality (HR: 0.87; 
95% CI: 0.66‒0.92; p=0.041) (Model 3). Finally, we carried 
out further adjustments for RIFLE and contributing factors, 
however, they did not change the benefit for 28-day mortality 
of the SCT approach (HR: 0.91; 95% CI: 0.63‒0.94; 
p=0.047) (Model 4) (Table 5).
DISCUSSION
In this study, we found that the SCT approach for managing 
CRRT increased survival at 28-day intervals in AKI pa-
tients. Furthermore, all-cause mortality was decreased by 
9.0% in the SCT group, in comparison with the non-SCT 
group (p=0.046). These findings suggest that well-trained 
CRRT team approaches may have beneficial effects on 
clinical outcomes in AKI patients treated with CRRT in the 
ICU. The down time per day and RBC-transfused number 
version 18.0 (SPSS Inc., Chicago, IL, USA). Continuous 
variables are presented as mean±standard deviation and 
categorical variables as numbers and percentages, if they 
were statistically normally distributed, and they were com-
pared using Student’s t-test for continuous variables and the 
χ2 test for categorical variables. However, medians and in-
terquartile ranges are presented unless variables are clearly 
normally distributed, and they were compared using Mann-
Whitney test. In the present study, we evaluated 28-day all-
cause mortality as an endpoint.
Based on the SCT-processing, we divided these enrolled 
patients into two groups, a SCT group and a non-SCT group. 
Survival curves were designed using the Kaplan-Meier meth-
od, and comparisons were made using the log-rank test. 
The impact of SCT control on 28-day mortality in AKI pa-
tients treated with CRRT was determined using the Cox 
proportional hazards model, and the results were presented 
as hazard ratios (HRs) and 95% confidence intervals (CIs). 
Especially, variables less than 0.1 of p-value in univariate 
analysis, including age and gender, were used for multivari-
ate analysis. All tests were two-sided, and p<0.05 was con-
sidered significant.
RESULTS
 
Baseline characteristics
The baseline characteristics of these patients are shown in 
Table 3. The mean age was 62.1 years, and 351 patients 
(63.7%) were male. The most common comorbid disease 
was malignancy (52.1%), followed by hypertension (37.2%) 
and diabetes mellitus (29.8%). In 206 patients (37.4%), 
CRRT was started at the ‘risk’ stage of the risk, injury, fail-
ure, loss and end kidney disease (RIFLE) classification, and 
287 patients (52.1%) were treated with CRRT due to sepsis.
At the time of CRRT application, the mean APACHE II, 
SOFA score, and age-adjusted CCI were 27.3, 12.3, and 5.8, 
respectively. The mean hemoglobin (Hb) concentration was 
9.2 g/dL, white blood cell count 14.6×103/mm3, platelet 
count 141.0×103/mm3, blood urea nitrogen level 54.7 mg/dL, 
and serum creatinine concentration 3.5 mg/dL. The mean to-
tal cholesterol level was 93.4 mg/dL, serum albumin concen-
tration 2.7 g/dL, and C-reactive protein (CRP) level was 13.1 
mg/dL, indicating that most patients were in inflammatory 
and undernourished conditions. In addition, arterial pH was 
7.3, serum total bilirubin 3.8 mg/dL, serum sodium 137.8, 
potassium 4.3, and bicarbonate (HCO3-) was 19.5 mEq/L.
Youn Kyung Kee, et al.
Yonsei Med J   http://www.eymj.org   Volume 56   Number 3   May 2015662
improving clinical outcomes in AKI patients when treated 
with CRRT. The SCT activities contributing to improving 
these factors were increased specialty and rapidity in solv-
during CRRT treatment were significantly reduced after 
SCT management compared with non-SCT management, 
and these factors are considered to play important roles in 
Table 3. Baseline Characteristics at the Time of CRRT Start in AKI Patients Treated with CRRT
Variables Total (n=551) Non-SCT group (n=253) SCT group (n=298) p value
Demographic data
    Age (yrs)   62.1±14.6   63.4±13.6   61.6±15.1 0.19
    Male (%) 351 (63.7) 150 (59.3) 200 (67.1) 0.11
    MAP (mm Hg)   79.5±16.6   80.5±17.4   78.1±16.1 0.13
    APACHE II score 27.3±7.7 28.6±8.4 27.1±7.0 0.06
    SOFA score 12.3±3.1 12.4±3.0 12.3±3.2 0.91
RIFLE, n (%) 0.27
    Risk 206 (37.4)   86 (34.0) 120 (40.3)
    Injury 205 (37.2) 104 (41.1) 101 (33.9)
    Failure 140 (25.4)   63 (24.9)   77 (25.8)
Contributing factor, n (%) 0.89
    Sepsis 287 (52.1) 129 (51.0) 158 (53.0)
    Hemodynamic instability 
      without sepsis 177 (32.1)   84 (33.2)   93 (31.2)
    Major surgery   87 (15.8)   40 (15.8)   47 (15.8)
Use of anticoagulation (%) 428 (77.7) 203 (80.2) 225 (75.5) 0.21
Biochemical data
    Hb (g/dL)   9.2±1.8   9.2±1.8   9.2±1.8 0.98
    WBC (103/mm3)   14.6±12.1   15.6±12.2   14.1±10.6 0.17
    Platelet (×103/mm3)   141.0±115.5   135.1±113.9   144.5±116.5 0.40
    BUN (mg/dL)   54.7±28.1   57.9±27.3   53.9±29.5 0.13
    Cr (mg/dL)   3.5±2.1   3.4±1.9   3.5±2.3 0.68
    T. cholesterol (mg/dL)   93.4±44.2   95.2±45.5   92.0±43.4 0.46
    Albumin (g/dL)   2.7±0.6   2.6±0.6   2.7±0.6 0.11
    CRP (mg/dL)   13.1±12.5   14.3±12.0   12.3±12.7 0.10
    Arterial pH   7.3±0.3   7.4±0.1   7.3±0.4 0.18
    T. bilirubin (mg/dL)   3.8±6.7   4.0±7.2   3.7±6.4 0.62
HCO3- (mEq/L) 19.5±5.3 19.9±4.9 19.2±5.5 0.15
BMI 23.0±5.3
Age-adjust CCI   5.8±2.3
CRRT, continuous renal replacement therapy; AKI, acute kidney injury; BMI, body mass index; RIFLE, risk, injury, failure, loss, and end kidney disease; 
APACHE, Acute Physiology and Chronic Health Evaluation; SOFA, Sequential Organ Failure Assessment; CCI, Charlson Comorbidity Index; MAP, mean arte-
rial pressure; Hb, hemoglobin; WBC, white blood cell; BUN, blood urea nitrogen; Cr, creatinine; CRP, C-reactive protein; SCT, specialized continuous renal 
replacement therapy team.
Data are n (%), mean±SD.
Table 4. Comparisons of CRRT Outcomes between Two Groups at the 28-Day Follow-Up
Non-SCT group (n=253) SCT group (n=298) p value
Total CRRT time (days)      7 (1‒48)      4 (1‒33) 0.033
Down-time per day (hrs)   5.1 (3.7‒15.4)   3.2 (2.8‒5.9) 0.002
Ultrafiltration rate (mL/kg/hr) 23.5 (20.5‒28.0) 27.9 (25.3‒30.2) 0.037
Number of TF during CRRT      9 (1‒22)      6 (1‒13) 0.011
ICU length of day (days)    21 (8‒37)    18 (8‒26) 0.037
CRRT mortality (%)  176 (69.5)  165 (55.3) 0.031
Number of dialyzers during 48 hrs 1.28 (1‒2.4) 1.87 (1‒4) 0.042
CRRT, continuous renal replacement therapy; non-SCT, conventional team approach; SCT, specialized CRRT team; TF, transfusion; ICU, intensive care unit.
Data are n (%), median (interquartile ranges).
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es and blood loss in patients.15,16 In this study, down time 
and numbers of blood transfusion were significantly lower 
than before SCT management. Because CRRT machines 
give a warning sign before complete circuit-stopping, CRRT 
circuit management is controlled properly, and therefore, 
circuit exchange originated from circuit failure is not neces-
sarily required. Moreover, the CRRT machines are highly 
complicated and require operating skill. Consequently, 
there should be specialized approach for quick and accurate 
problem solving. Because well trained CRRT team with 
specialty and many experiences could more quickly and 
properly solve the problems such as circuit halt, vascular 
access related problems and mechanical errors, down time, 
blood loss and the number of circuit exchanges would be 
lower in SCT group than non-SCT group. In this study, cir-
cuit-exchanges were conducted regularly after 48 hrs of use, 
even if the blood pumps were not stopped. We investigated 
ing problems by well-trained members who could focus on 
CRRT related tasks seperated from ICU general care. 
We considered that the most significant change after SCT 
approach was to add 5 CRRT nurses to CRRT management. 
CRRT nurses have to go through more educational programs 
for CRRT management (ex; CRRT kit changes, anticoagula-
tion use, and ultrafiltration dose etc.) in addition to general 
ICU care (Table 1). Gilbert, et al.12 reported that CRRT pro-
gram definitely enhanced the level of care of the patient by 
allowing the “bedside-nurse” to concentrate on general pa-
tient care (ex; turning, suctioning, medication administration, 
overall management and documentation) free from CRRT-
related tasks. At the same time, the trained CRRT-nurse 
could entirely focus on the CRRT treatment, thereby provid-
ing an additional care and minimizing potential mistakes. 
Moreover, regular interval rounding by CRRT nurses made 
it possible to continuously access to patients’ hemodynamic 
status and CRRT operating status, which could be beneficial 
for detection and solving problems promptly. Furthermore, 
they are also in charge for education of bed-side nurse for 
basic CRRT management. Besides addition of CRRT nurs-
es, the SCT monthly meeting for quality control could make 
it possible to regularly check the problems related to CRRT 
management and discuss with each other. Moreover, such 
regular meeting and discussion could make CRRT-nurses 
more professional and skillful. Therefore, we infer that pro-
fessional and well-organized training and regular feedback 
system could get better quality of CRRT management, and 
consequentially, might have an effect on favorable clinical 
outcomes.
CRRT has been preferred by patients with hemodynamic 
instability to control uremia, electrolyte, acid-base and vol-
ume balance in many ICUs.9 However, prolonged blood 
pump halting and prolonged manipulation time for the re-
placement of circuit can result in inadequate treatment dos-
Table 5. Cox Proportional Hazards Analysis for 28-Day Mortality Based on SCT
Compared with non-SCT management
HR 95% CI p value
Model 1 0.77 0.63‒0.95 0.016
Model 2 0.76 0.58‒0.98 0.039
Model 3 0.87 0.66‒0.92 0.041
Model 4 0.91 0.69‒0.94 0.046
SCT, specialized CRRT team; CRRT, continuous renal replacement therapy; non-SCT, conventional team approach; HR, hazard ratio; CI, confidence interval; 
MAP, mean arterial pressure; APACHE, Acute Physiology and Chronic Health Evaluation; SOFA, Sequential Organ Failure Assessment; CRP, C-reactive pro-
tein; eGFR, estimated glomerular filtration rate; RIFLE, risk, injury, failure, loss, and end kidney disease. 
Model 1: unadjusted relative risk. Model 2: adjusted for age, gender, MAP, APACHE II score and SOFA score, CRP. Model 3: adjusted for Model 2 plus, 
hemoglobin, albumin, eGFR, total cholesterol, total bilirubin. Model 4: adjusted for Model 3 plus RIFLE and contributing factors.
Fig. 2. Kaplan-Meier plots for cumulative 28-day mortality. 28-day all-cause 
mortality rates after the SCT approach were significantly reduced (log rank 
p=0.016). non-SCT, conventional team approach; SCT, specialized continu-
ous renal replacement therapy team.
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acteristics of these patients are quite heterogeneous and risk 
factors for mortality of patients requiring CRRT are fre-
quently inter-related. Second, these two groups (non-SCT 
group vs. SCT group) were not conducted at the same time. 
However, the gap of the periods was less than 6 month, the 
same ICU policy was applied to patients at a single center, 
and the patients in this study experienced no differences in 
decision-making process because of same nephrologist and 
ICU specialists. Moreover, there were no remarkable differ-
ences in indications for CRRT, filter types, anticoagulation 
types and management between the two groups. Further-
more, as shown in Table 3, there were no significant differ-
ences in the baseline characteristics between the two groups, 
except for estimated glomerular filtration rate level. There-
fore, the bias caused by the different time may be negligi-
ble. However, in regard with ICU clinical care practices, 
there would be differences between two groups, because of 
adding CRRT nurses and separating general care from 
CRRT related tasks. This was important change in SCT 
management which could have influences on clinical out-
comes. Third, because there are diversities in physician fac-
tors, critical care programs, patient to nurse ratios and ICU 
systems, depending on centers, we are not certain whether 
identical result would be found in all other centers. Never-
theless, a major strength of this study is that it is based on a 
relatively large number of patients requiring CRRT.
In conclusion, a well-trained CRRT team may be benefi-
cial for the management of AKI patients requiring CRRT 
treatment. However, additional multicenter studies are re-
quired to confirm these findings.
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